In 2014 the American College of Cardiology/American Heart Association issued four new guidelines for cardiovascular disease prevention that focused on cardiovascular risk assessment,lifestyle management,obesity manage...In 2014 the American College of Cardiology/American Heart Association issued four new guidelines for cardiovascular disease prevention that focused on cardiovascular risk assessment,lifestyle management,obesity management,and blood cholesterol management.The development of an atherosclerotic cardiovascular disease risk calculator formed the basis of the risk assessment guideline,and the lifestyle management guideline focused on recommending an evidence-based dietary pattern.The blood cholesterol management guideline specifi cally identifi ed four groups of patients shown to benefi t from moderate-intensity or high-intensity statin therapy from previous clinical trials and abandoned the use of specifi c low-density lipoprotein(LDL)cholesterol(LDL-C)goal levels on the basis of the lack of clinical trial evidence.The recommendations for treatment with moderate-intensity or high-intensity statin therapy are based on rigorous evidence from randomized clinical trials.Guidance has since been provided for the use of nonstatin therapies,including cholesterol absorption inhibitor and proprotein convertase subtilisin/kexin type 9 monoclonal antibody therapy when adequate reduction of LDL-C levels is not achieved with maximally tolerated statin therapy.The recent development and application of these therapies have resulted in remarkable reductions in LDL-C levels that are well tolerated,and preliminary outcome data are promising in showing substantial atherosclerotic cardiovascular disease event reductions beyond statin therapy.展开更多
文摘In 2014 the American College of Cardiology/American Heart Association issued four new guidelines for cardiovascular disease prevention that focused on cardiovascular risk assessment,lifestyle management,obesity management,and blood cholesterol management.The development of an atherosclerotic cardiovascular disease risk calculator formed the basis of the risk assessment guideline,and the lifestyle management guideline focused on recommending an evidence-based dietary pattern.The blood cholesterol management guideline specifi cally identifi ed four groups of patients shown to benefi t from moderate-intensity or high-intensity statin therapy from previous clinical trials and abandoned the use of specifi c low-density lipoprotein(LDL)cholesterol(LDL-C)goal levels on the basis of the lack of clinical trial evidence.The recommendations for treatment with moderate-intensity or high-intensity statin therapy are based on rigorous evidence from randomized clinical trials.Guidance has since been provided for the use of nonstatin therapies,including cholesterol absorption inhibitor and proprotein convertase subtilisin/kexin type 9 monoclonal antibody therapy when adequate reduction of LDL-C levels is not achieved with maximally tolerated statin therapy.The recent development and application of these therapies have resulted in remarkable reductions in LDL-C levels that are well tolerated,and preliminary outcome data are promising in showing substantial atherosclerotic cardiovascular disease event reductions beyond statin therapy.
